Business Strategy Siegfried Inaugurates API Production Facility in Germany

Source: Press release Siegfried 1 min Reading Time

Related Vendors

Siegfried has recently inaugurated its new large-scale production facility for API manufacturing in Minden, Germany. With this, the company strengthens its position as one of the leading global CDMOs for small molecule drug substances.

The facility adds 100 m³ of reactor capacity and strengthens Siegfried’s position as one of the leading global CDMOs for small molecule drug substances. (Source:  Siegfried)
The facility adds 100 m³ of reactor capacity and strengthens Siegfried’s position as one of the leading global CDMOs for small molecule drug substances.
(Source: Siegfried)

Zofingen/Switzerland – Siegfried, a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen, Switzerland, has recently inaugurated its new large-scale production facility for API manufacturing in Minden, Germany.

The facility adds 100 m³ of reactor capacity and strengthens Siegfried’s position as one of the leading global CDMOs for small molecule drug substances. It enhances the company’s ability to support customers with complex, high-quality and scalable API manufacturing solutions.

Marcel Imwinkelried, CEO: “The inauguration of our new Minden facility is an important milestone in the continued expansion of our global manufacturing network. It strengthens our ability to support customers with complex API manufacturing at commercial scale and underlines our commitment to reliable, flexible and high-quality supply.”

The new plant combines advanced process technology, automation, and high-containment capabilities. Features such as gravity-flow processing, RFID-enabled recipe management, and optimized solvent handling contribute to efficient, safe and reliable production.

With the new facility, Siegfried further expands its large-scale drug substances offering and reinforces its strategic focus on network strength, operational excellence, and trusted long-term partnerships with pharmaceutical customers.

(ID:50873909)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent